Видео ютуба по тегу Esr1 Mutation

Breast Cancer Breakthroughs: The Importance of ESR1 mutations in metastatic breast cancer
Breast Cancer Breakthroughs: The Importance of ESR1 mutations in metastatic breast cancer
ELAINE 1: ESR1 mutations in ctDNA from ER+/HER2- mBC treated with lasofoxifene or fulvestrant
ELAINE 1: ESR1 mutations in ctDNA from ER+/HER2- mBC treated with lasofoxifene or fulvestrant
Understanding Progression: How to Identify and Treat ESR1 Mutations in HR+ MBC
Understanding Progression: How to Identify and Treat ESR1 Mutations in HR+ MBC
Dr. Fuqua on ESR1 Mutations in Primary Breast Cancer
Dr. Fuqua on ESR1 Mutations in Primary Breast Cancer
SABCS 2021:
SABCS 2021: "Transcriptional reprogramming, ESR1 mutations, and novel targets and treatment"
ESR1 Mutation: The Need for & Role of Testing in ER+/ HER2- Advanced or Metastatic Breast Cancer
ESR1 Mutation: The Need for & Role of Testing in ER+/ HER2- Advanced or Metastatic Breast Cancer
Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer
Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer
ESR1 mutation in untreated EC: prevalence, characteristics and prognosis from the UTOLA trial
ESR1 mutation in untreated EC: prevalence, characteristics and prognosis from the UTOLA trial
ESR1 testing guides treatment in metastatic breast cancer
ESR1 testing guides treatment in metastatic breast cancer
ESR1 Mutations in Metastatic Breast Cancer: Should I get tested?
ESR1 Mutations in Metastatic Breast Cancer: Should I get tested?
ESR1 Mutations in Breast Cancer | Insights from Dr Wassim Mchayleh
ESR1 Mutations in Breast Cancer | Insights from Dr Wassim Mchayleh
Dr. Goncalves Describes Research Involving the ESR1 Mutation in Breast Cancer
Dr. Goncalves Describes Research Involving the ESR1 Mutation in Breast Cancer
Dr. Tolaney on Presence of PIK3CA and ESR1 Mutations in MONARCH 2 Trial in Breast Cancer
Dr. Tolaney on Presence of PIK3CA and ESR1 Mutations in MONARCH 2 Trial in Breast Cancer
ESR1 Mutations in Focus: Are PROTACs the Next Breakthrough?
ESR1 Mutations in Focus: Are PROTACs the Next Breakthrough?
New Horizons in ESR1-Mutated Breast Cancer
New Horizons in ESR1-Mutated Breast Cancer
Treatment Options for Patients with ESR1 Mutated Breast Cancer after CDK4/6i Progression
Treatment Options for Patients with ESR1 Mutated Breast Cancer after CDK4/6i Progression
Unlocking ESR1 Mutations in Breast Cancer
Unlocking ESR1 Mutations in Breast Cancer
Understanding ESR1 Mutations in HR+, HER2- Metastatic Breast Cancer
Understanding ESR1 Mutations in HR+, HER2- Metastatic Breast Cancer
Dr. Goetz on Treatment Challenges for ESR1-Mutant Breast Cancer
Dr. Goetz on Treatment Challenges for ESR1-Mutant Breast Cancer
ESR1 Mutated Metastatic Breast Cancer Market Size was ~USD 800 Million in 2022
ESR1 Mutated Metastatic Breast Cancer Market Size was ~USD 800 Million in 2022
SABCS 2023: State of the Art - Targeting Mutant ER
SABCS 2023: State of the Art - Targeting Mutant ER
ESR1 Mutations: Understanding your Test Results
ESR1 Mutations: Understanding your Test Results
Dr. Graff on Current Treatments in ESR1-Mutant Breast Cancer
Dr. Graff on Current Treatments in ESR1-Mutant Breast Cancer
Monitoring ESR1 ctDNA During First-Line Care of HR-Positive Advanced Breast Cancer: A New Approach
Monitoring ESR1 ctDNA During First-Line Care of HR-Positive Advanced Breast Cancer: A New Approach
Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer
Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer